An investigational genetic test may not only be able to differentiate women likely to have early recurrence of estrogen receptor-positive breast cancer, but also could lead to novel combinations of existing drugs to treat these patients earlier in the disease process, according to Dr. Minetta C. Liu. See the related story at http://tinyurl.com/dy5d6sm
All Comments